BACKGROUND: Tumor necrosis factor (TNF) antagonists [e.g., TNF soluble receptor (TNFsr)] improved survival in preclinical but not clinical sepsis trials. However fluid support-itself beneficial-is standard clinically but rarely employed in preclinical sepsis models. We hypothesized that these therapies may not have additive benefit. METHODS AND RESULTS: Antibiotic-treated rats (n = 156) were randomized to intratracheal or intravenous Escherichia coli challenges (>LD50) and either placebo or TNFsr and 24 h fluid treatments alone or together. The survival effects of these therapies did not differ significantly comparing challenge routes. When averaged across route, while TNFsr or fluid alone decreased the hazard ratio of death significantly [ln ± standard error (SE): -0.65 ± 0.30 and -0.62 ± 0.30, respectively, p ≤ 0.05], together they did not (p = 0.16). Furthermore, the observed effect of TNFsr and fluid together on reducing the hazard ratio was significantly less than estimated (-0.37 ± 0.29 versus -1.27 ± 0.43, respectively, p = 0.027) based on TNFsr and fluid alone. While each treatment increased central venous pressure at 6 and 24 h, the observed effects of the combination were also less than estimated ones (p ≤ 0.0005). CONCLUSIONS: The individual survival benefits of TNFsr and fluids were not additive in this rat sepsis model. Investigating new sepsis therapies together with conventional ones during preclinical testing may be informative.
BACKGROUND:Tumor necrosis factor (TNF) antagonists [e.g., TNF soluble receptor (TNFsr)] improved survival in preclinical but not clinical sepsis trials. However fluid support-itself beneficial-is standard clinically but rarely employed in preclinical sepsis models. We hypothesized that these therapies may not have additive benefit. METHODS AND RESULTS: Antibiotic-treated rats (n = 156) were randomized to intratracheal or intravenous Escherichia coli challenges (>LD50) and either placebo or TNFsr and 24 h fluid treatments alone or together. The survival effects of these therapies did not differ significantly comparing challenge routes. When averaged across route, while TNFsr or fluid alone decreased the hazard ratio of death significantly [ln ± standard error (SE): -0.65 ± 0.30 and -0.62 ± 0.30, respectively, p ≤ 0.05], together they did not (p = 0.16). Furthermore, the observed effect of TNFsr and fluid together on reducing the hazard ratio was significantly less than estimated (-0.37 ± 0.29 versus -1.27 ± 0.43, respectively, p = 0.027) based on TNFsr and fluid alone. While each treatment increased central venous pressure at 6 and 24 h, the observed effects of the combination were also less than estimated ones (p ≤ 0.0005). CONCLUSIONS: The individual survival benefits of TNFsr and fluids were not additive in this ratsepsis model. Investigating new sepsis therapies together with conventional ones during preclinical testing may be informative.
Authors: Peter Q Eichacker; Chantal Parent; Andre Kalil; Claire Esposito; Xizhong Cui; Steven M Banks; Eric P Gerstenberger; Yvonne Fitz; Robert L Danner; Charles Natanson Journal: Am J Respir Crit Care Med Date: 2002-11-01 Impact factor: 21.405
Authors: M Knotek; B Rogachev; W Wang; T Ecder; V Melnikov; P E Gengaro; M Esson; C L Edelstein; C A Dinarello; R W Schrier Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: Claire V Murphy; Garrett E Schramm; Joshua A Doherty; Richard M Reichley; Ognjen Gajic; Bekele Afessa; Scott T Micek; Marin H Kollef Journal: Chest Date: 2009-03-24 Impact factor: 9.410
Authors: Waheedullah Karzai; Xizhong Cui; Bjoern Mehlhorn; Eberhard Straube; Thomas Hartung; Eric Gerstenberger; Steven M Banks; Charles Natanson; Konrad Reinhart; Peter Q Eichacker Journal: Anesthesiology Date: 2003-07 Impact factor: 7.892
Authors: Xizhong Cui; Chantal Parent; Heather Macarthur; Scott D Ochs; Eric Gerstenberg; Steve Solomon; Yvonne Fitz; Robert L Danner; Steven M Banks; Charles Natanson; Daniela Salvemini; Peter Q Eichacker Journal: J Appl Physiol (1985) Date: 2004-05-28
Authors: C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo Journal: J Exp Med Date: 1989-03-01 Impact factor: 14.307
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-01-04 Impact factor: 17.440